These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2694799

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Madopar HBS and the decompensated phase of Parkinson disease.
    Caraceni T, Nordera N, Lamperti E, Lorizio A.
    Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
    [Abstract] [Full Text] [Related]

  • 10. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.
    Eur Neurol; 1987 Aug; 27 Suppl 1():54-8. PubMed ID: 3322837
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Rev Neurol (Paris); 1987 Aug; 143(11):746-52. PubMed ID: 3324265
    [Abstract] [Full Text] [Related]

  • 15. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK, Mondal KN.
    Pharmatherapeutica; 1986 Aug; 4(9):571-6. PubMed ID: 3094036
    [Abstract] [Full Text] [Related]

  • 16. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP, Marion MH, Marsden CD.
    Eur Neurol; 1987 Aug; 27 Suppl 1():105-13. PubMed ID: 3322834
    [Abstract] [Full Text] [Related]

  • 17. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.
    Eur Neurol; 1987 Aug; 27 Suppl 1():88-92. PubMed ID: 3322841
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Eur Neurol; 1987 Aug; 27 Suppl 1():114-9. PubMed ID: 3322835
    [Abstract] [Full Text] [Related]

  • 20. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.